Author:
Alonso Ana,Alcolea Pedro José,Larraga Jaime,Peris María Paz,Esteban Adriana,Cortés Alberto,Ruiz-García Silvia,Castillo Juan Antonio,Larraga Vicente
Abstract
Leishmania infantum is the etiological agent of zoonotic visceral leishmaniasis (ZVL). The disease is endemic in Central and South America, Central and South East Asia, and the Mediterranean basin. Dogs are the main reservoir, with an estimated prevalence of approximately 2.5 million dogs in Southern Europe. Current treatments cause side effects, disease recurrence, and drug resistance. Therefore, the development of vaccines against canine leishmaniasis is necessary. We have generated a DNA vaccine based on the non-replicative antibiotic resistance marker-free plasmid vector pPAL that contains the encoding gene for the L. infantum activated protein kinase C receptor analog (LACK). Homologous pPAL-LACK prime-boost intranasal administration confers efficacious protection in Beagle dogs with a reduction of clinical signs and a statistically significant reduction of the parasite burden in the bone marrow of more than 90% of dogs after experimental infection with highly infective promastigotes. This DNA vaccine elicits a robust cellular immune response skewed towards the Th1 profile.
Subject
Immunology,Immunology and Allergy
Reference62 articles.
1. Canine leishmaniasis: pathological and ecological factors influencing transmission of infection;Abranches;J Parasitol,1991
2. [Canine leishmaniasis in Spain: data for the clinician];Ferrer;Enferm Infecc Microbiol Clin,1989
3. Evora district as a new focus for canine leishmaniasis in Portugal;Semiao-Santos;Parasitol Res,1995
4. Leishmania and human immunodeficiency virus coinfection: the first 10 years;Alvar;Clin Microbiol Rev,1997
5. Leishmania / HIV co-infections;Desjeux;Afr Health,1995